Caplin Point Laboratories’ arm gets USFDA nod for Prochlorperazine Edisylate Injection

23 Apr 2021 Evaluate

Caplin Steriles (Caplin), a Subsidiary Company of Caplin Point Laboratories, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Prochlorperazine Edisylate Injection USP, 10 mg/2 mL (5 mg/mL) Vials presentations, a generic therapeutic equivalent version of (RLD), COMPAZINE Injection, of SmithKlineBeecham Corporation, USA.

Prochlorperazine Edisylate Injection is an antiemetic and is indicated for the control of severe nausea and vomiting. According to IQVIA (IMS Health), Prochlorperazine Edisylate Injection had US sales data of approximately $17 million for the 12-month period ending Dec 2020.

Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.

Caplin Point Lab Share Price

1661.90 -26.70 (-1.58%)
13-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1800.50
Dr. Reddys Lab 1293.00
Cipla 1314.10
Zydus Lifesciences 906.00
Lupin 2314.85
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×